Amgen’s Enbrel for Psoriasis
April 30, 2004 by admin · Leave a Comment
On April 30, 2004 Amgen Inc. announced that its biological therapy Enbrel® (etanercept) had received approval from the FDA. The drug is approved for the treatment of psoriasis in adult patients who are candidates for systemic therapy and who suffer from chronic moderate-to-severe plaque psoriasis. This most recent approval adds to Enbrel’s previously approved indications [...]
Surveillance Summary Feb 7 – Feb 13, 2004
February 13, 2004 by admin · Leave a Comment
Our surveillance program experienced moderate activity throughout week 7 of 2004. A total of 19 technology updates were recorded; 12 of these were new technologies added to our database, while the remaining 7 updates occurred for already existing technology records. Etanercept, Remicade and Visudyne were the only High Impact technologies updated during week 7. Please [...]